Nanoviricides (NNVC) Total Current Liabilities (2011 - 2026)
Nanoviricides (NNVC) posted Total Current Liabilities of $1.1 million for Q1 2026, down 10.91% sequentially from $1.2 million in Q4 2025, and down 11.14% YoY from $1.2 million in Q1 2025.
Nanoviricides (NNVC) Total Current Liabilities (2011 - 2026) Analysis & Trends
Nanoviricides has reported Total Current Liabilities for 16 years, with the latest figure at $1.1 million in Q1 2026.
- Quarterly Total Current Liabilities fell 11.14% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 11.14% YoY) and the FY2025 annual result came in at $1.3 million, down 3.85% from the prior year.
- Total Current Liabilities declined to $1.1 million in Q1 2026 per NNVC's latest filing, from $1.2 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $1.6 million in Q3 2024 and troughed at $348744.0 in Q1 2023.
- A 5-year average of $911936.9 and a median of $951074.0 in 2023 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2022 and 2024: Total Current Liabilities plunged 55.62% in 2022, then jumped 154.33% in 2024.
- Over 5 years, Total Current Liabilities stood at $464592.0 in 2022, then soared by 104.71% to $951074.0 in 2023, then rose by 24.5% to $1.2 million in 2024, then climbed by 1.0% to $1.2 million in 2025, then declined by 10.91% to $1.1 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $1.1 million, $1.2 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Nanoviricides | 28.74 Mn | 25.53 Mn | - | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.07 Mn |
| Dec 31, 2025 | 1.20 Mn |
| Sep 30, 2025 | 1.18 Mn |
| Jun 30, 2025 | 1.31 Mn |
| Mar 31, 2025 | 1.20 Mn |
| Dec 31, 2024 | 1.18 Mn |
| Sep 30, 2024 | 1.63 Mn |
| Jun 30, 2024 | 1.36 Mn |
| Mar 31, 2024 | 813,337.00 |
| Dec 31, 2023 | 951,074.00 |
| Sep 30, 2023 | 948,311.00 |
| Jun 30, 2023 | 534,250.00 |
| Mar 31, 2023 | 348,744.00 |
| Dec 31, 2022 | 464,592.00 |
| Sep 30, 2022 | 518,358.00 |
| Jun 30, 2022 | 412,837.00 |
| Mar 31, 2022 | 386,731.00 |
| Dec 31, 2021 | 344,285.00 |
| Sep 30, 2021 | 869,467.00 |
| Jun 30, 2021 | 351,146.00 |